The pathophysiology of COVID-19 causing GBS involves SARS-CoV-2 using angiotensin-converting enzyme 2 (ACE-2) receptors to enter host cells, affecting the lungs, gastrointestinal tract, cardiomyocytes, urothelial cells, and proximal tubular cells [11]. Here, ACE2 is linked to COVID-19.